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Induction of endotoxin tolerance leads to a reduced inflam-
matory response after repeated challenge by LPS and is impor-
tant for resolution of inflammation and prevention of tissue
damage. Enterobacterial LPS is recognized by the TLR4 signal-
ing complex, whereas LPS of some non-enterobacterial organ-
isms is capable of signaling independently of TLR4 utilizing
TLR2-mediated signal transduction instead. In this study we
report that Porphyromonas gingivalis LPS, a TLR2 agonist, fails
to induce a fully endotoxin tolerant state in a humanmonocytic
cell line (THP-1) and mouse bone marrow-derived macro-
phages. In contrast to significantly decreased production of
human IL-8 andTNF- and, inmice, keratinocyte-derived cyto-
kine (KC), macrophage inflammatory protein-2 (MIP-2), and
TNF- after repeated challenge with Escherichia coli LPS, cells
repeatedly exposed to P. gingivalis LPS responded by producing
less TNF- but sustained elevated secretion of IL-8, KC, and
MIP-2. Furthermore, in endotoxin-tolerant cells, production of
IL-8 is controlled at the signaling level and correlates well with
NF-B activation, whereas TNF- expression is blocked at the
gene transcription level. Interferon plays an important role in
attenuation of chemokine expression in endotoxin-tolerized
cells as shown in interferon regulatory factor-3 knock-outmice.
In addition, human gingival fibroblasts, commonly known not
to display LPS tolerance, were found to be tolerant to repeated
challenge by LPS if pretreated with interferon . The data sug-
gest that the inability of the LPS-TLR2 complex to induce full
endotoxin tolerance in monocytes/macrophages is related to
diminished production of interferon  and may partly explain
the involvement of these LPS isoforms in the pathogenesis of
chronic inflammatory diseases.
Detection of pathogen-associated molecular patterns by
Toll-like receptors (TLRs)2 expressed on innate immune cells
triggers a robust and essential inflammatory reaction. Inflam-
mation as a well coordinated process that comprises increased
vascular permeability, migration of polymorphonuclear leuko-
cytes, monocytes, and lymphocytes into affected tissues, and
activation of cells to secrete inflammatorymediators is essential
for host defense (1). If it is well controlled and resolved in a
timely manner, it benefits the host by elimination of the invad-
ing pathogen. Otherwise, prolonged or excessive inflammation
leads to chronicity and tissue damage (2).
Toll-like receptors represent a family of evolutionarily highly
conserved transmembrane molecules that act as pathogen rec-
ognition receptors. To date, 13 mammalian TLRs have been
identified, and each appears to be required for responses to a
different class of infectious pathogen (3). Almost immediately
aftermicrobes invade,microbial products signal throughTLRs,
broadly distributed on immune cells, activating these cells to
produce proinflammatory cytokines, interferons, histamine,
and antimicrobial peptides (4). Toll-like receptor signaling rep-
resents a principalmolecular pathway for host innate immunity
(5). All members of the TLR superfamily signal in a similar
manner and activate common signaling pathways, most nota-
bly those leading to the activation of the transcription factors
NF-B and IRF (6).
TLR signalingmay be divided into twodistinct pathways; one
leading to the MyD88-dependent arm-triggering expression of
proinflammatory cytokines and the other leading to the
MyD88-independent arm (TRIF/TRAM-mediated) responsi-
ble for interferon type I production (7). Myeloid differentiation
factor 88 (MyD88)-dependent signaling is common to all the
TLRs except TLR3, which exclusively utilizes the myeloid dif-
ferentiation factor 88-independent pathway. TLR4 is unique in
that it can trigger both the MyD88-dependent and MyD88-
independent pathways (8). Signaling through the TLR4 path-
way is one of the principalmolecularmechanisms for the detec-
tion of Gram-negative pathogens and their LPS by host
immune cells (9). The rapid response against LPS can be of
benefit to the host in moderate levels by promoting inflamma-
tion and priming the immune system to eradicate the invading
pathogens. However, an excessive response to LPS, which is not
properly resolved, can lead to chronic inflammatory conditions
(10).
One of the mechanisms involved in the regulation of the
inflammatory response is the phenomenon of endotoxin toler-
ance. Endotoxin tolerance is a protective mechanism in which
repeated exposure of host immune cells to endotoxin results in
repressed expression of proinflammatory cytokines (11). This
phenomenon was attributed to the monocyte/macrophage line-
age of the human immune system and was reproduced in ani-
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mal models and reported in humans (12). On the other hand,
human skin and gingival fibroblasts, which do not display LPS
tolerance or negative regulators of inflammatory response,
were shown to sustain an inflammatory response in the pres-
ence of virulence factors (13). Most known regulatory mecha-
nisms target the TLR signaling pathway and thus broadly
inhibit multiple aspects of the inflammatory response (14). In
addition to this robust signaling-based control mechanism, an
elegant gene-specific regulatory mechanism exists to allow
individual aspects of the TLR-induced response and genes to be
differentially regulated (15). Over the past several years, many
negative regulators of TLRs have been identified, and this neg-
ative regulation is achieved at multiple levels ranging from
extracellular decoy receptors (soluble TLR4 and TLR2) and
membrane-bound suppressors (ST2, SIGIRR) to intracellular
inhibitors (IRAKM, SOCS1, NOD2, TOLLIP) and epigenetic
control of gene expression (16).
To date TLR4 seems to be the most heavily regulated of all
theTLRs (17). The reason for thismight be related to the poten-
tial, extreme toxicity of TLR4 signaling. Cells ofmyeloid lineage
are capable of recognizing picomolar quantities of LPS and
respond via several signal transduction cascades with the
release of a wide range of proinflammatory cytokines (18).
Enterobacterial LPS is recognized by a signaling complex com-
prising at least CD14, TLR4, and MD-2 (19). However, LPS of
non-enterobacterial organisms, such as Porphyromonas gingi-
valis, Bacteroides fragilis, Chlamydia trachomatis, and Helico-
bacter pylori are capable of signaling independent of TLR4 and
utilizing TLR2-mediated signal transduction instead (20).
Interestingly, all of these bacteria, in which LPS activate the
TLR2 signalingmechanism, are involved in the pathogenesis of
chronic inflammatory diseases: periodontitis, inflammatory
bowel disease, urogenital infection, and gastric ulcers, respec-
tively (21–24). The ability of these bacteria to cause chronic
inflammation could be a consequence of less defined LPS-TLR2
signaling control mechanisms and differential induction of
endotoxin tolerance by TLR4 and TLR2 agonists. Our aim was
to examine differences in the mechanism of induction of endo-
toxin tolerance by canonical Escherichia coli LPS, a TLR4 ago-
nist, and LPS isoforms, which activate TLR2.
We have already reported that impaired immune tolerance
to P. gingivalis LPS is responsible for neutrophil-dominated
chronic inflammation seen in periodontitis (25). In the current
studywe show that in contrast to E. coli LPS-induced tolerance,
which is characterized by the down-regulation of human IL-8
and TNF- and mouse KC, MIP-2, and TNF- production,
P. gingivalis LPS-pretreated human monocytes and mouse
bone marrow-derived macrophages remained able to secret
IL-8 and KC andMIP-2, respectively, but production of TNF-
was significantly decreased. Because E. coli LPS, as a TLR4 ago-
nist, activates both MyD88 and TRIF pathways and is con-
nected to successful down-regulation of cytokine/chemokine
production in endotoxin-tolerant cells and TLR2 signals only
through MyD88 pathway, we hypothesized that different con-
trolmechanisms for chemokine andTNF- production exist in
endotoxin-tolerant cells and that IFN- plays a pivotal role in
the control of the NF-B signaling cascade and chemokine
secretion.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—LPS from E. coli O55:B5 was
obtained from Sigma. LPS from P. gingivalis ATCC 33277 was
obtained from InvivoGen, San Diego, CA. MALDI-TOF mass
spectrometry of this P. gingivalis LPS revealed predominant
peaks corresponding to penta-acylated diphosphorylated lipid
A isoform, already proven to be a TLR2 agonist (26). Recombi-
nant human IFN- was purchased from Peprotech, and low
endotoxin azide-free-purified anti-human IFN- antibody was
from BioLegend. Mouse IgG1 isotype control to anti-IFN-
antibody was obtained from R&D Systems. Rabbit anti-IB-
IgG was from Cell Signaling, and goat anti-rabbit IgG HRP-
conjugated antibody was from Santa Cruz Biotechnology.
Cell Culture—Human THP-1 monocytes were obtained
from the European Collection of Cell Cultures (ECACC) and
maintained in RPMI 1640 medium supplemented with 10%
fetal calf serum, 2 mM L-glutamine, penicillin (100 units/ml),
and streptomycin (100 g/ml) (Invitrogen). THP-1 cells were
cultured at 37 °C, 100% humidity, and 5% CO2 at 5  105
cells/ml density. Bonemarrow-derivedmacrophages were pre-
pared from wild-type and IRF3 knock-out C57BL/6 mice (a
kind gift from Prof. T. Taniguchi, University of Tokyo) and
cultured for 1 week in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FCS, 1% penicillin/strepto-
mycin, and 1% L-glutamine. Proliferation was driven by granu-
locyte macrophage-colony-stimulating factor derived from
L929 supernatant. Human gingival fibroblasts (HGFs) were
established from explants of healthy gingival tissues obtained
during routine clinical procedures as described previously (27).
The study was approved by the Research Ethics Committee of
Northern Ireland, participant information sheets were pro-
vided, and written informed consent was obtained from
patients wishing to participate in the study. HGFs were cul-
tured to confluence in DMEM (Invitrogen) supplemented with
10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100
units/ml penicillin, and 100 g/ml streptomycin in a humidi-
fied atmosphere of 5% CO2 at 37 °C at 8 104 cells/ml density.
The cells between the 5th and 13th passages were used for
assays. Twenty-four hours before treatment the medium was
changed to 1% FCS DMEM supplemented with the same con-
centrations of antibiotics and glutamine.
Induction of Endotoxin Tolerance and Cytokine Mea-
surement—Amonocyte sepsis model was used for induction of
endotoxin tolerance (28). Briefly, THP-1 cells were treatedwith
1g/ml E. coli or P. gingivalis LPS for 24 h, washed 3 times with
serum-free medium, and re-treated once with the same con-
centration of LPS for 4 h. Mouse bone marrow-derived macro-
phageswere treatedwith 100 ng/ml LPS.Human gingival fibro-
blasts were treated with 10 ng/ml E. coli LPS and 10 g/ml
P. gingivalisLPS. Control cells were incubated inmediumalone
and re-treated in the same way as pretreated cells. Cell-free
supernatants from tolerized and naïve (preincubated in
medium alone) cells were collected after 4 h, and IL-8, KC,
MIP-2, and mouse TNF- were measured by ELISA kits
according to the manufacturer’s instructions (R&D Systems,
Abingdon, UK) as was human TNF- (PeproTech EC Ltd.,
London, UK). IFN- was measured in the cell supernatants
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after 24 h of treatment by ELISA (PBL Interferon Source). Cell
viability after 24 h or pretreatment was confirmed by MTT
assay (29).
Western Blot Analysis—THP-1 cells (5 105/ml) pretreated
with medium or LPS for 24 h were restimulated for the indi-
cated time periods noted in the figures and then lysed on ice for
30min in 35l of lysis buffer (20mMTris, pH7.4, 150mMNaCl,
1 mM EDTA, 1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxy-
cholate, 1 mM sodium orthovanadate, 1 mM sodium flouride, 1
mMPMSF, and proteinase inhibitor coctail (RocheApplied Sci-
ence)). Cell debris was pelleted by centrifugation, and superna-
tants were collected and stored at80 °C until assayed. Thirty
micrograms of total cellular protein were denatured at 100 °C
for 5min in loading buffer (60mMTris, 2.5% SDS, 10% glycerol,
5%mercaptoethanol, 0.01% bromphenol blue) and subjected to
10% SDS-PAGE. Gels were transferred to nitrocellulose mem-
branes and blocked with PBS containing 0.05% Tween 20
(PBS-T) and 5% nonfat milk powder for 1 h. After washing in
PBS-T, membranes were probed with rabbit anti-IB- IgG
(1:1000) (Cell Signaling) for 2 h at room temperature. Mem-
branes were then washed with PBS-T and incubated with a
polyclonal secondary goat anti-rabbit IgG HRP Ab (1:2000;
Santa Cruz Biotechnology) for 1 h at room temperature. After
three washes in PBS-T, membranes were developed using ECL
substrate (GEHealthcare) according to themanufacturer’s pro-
tocol (Thermo Scientific).
Quantitative Real-time PCR—Total RNA from control and
tolerized THP-1 cells treated with 1 g/ml E. coli and P. gingi-
valis LPS for 4 h was prepared using RNeasy kit (Qiagen)
according to the manufacturer’s instructions. One microgram
of total RNA was reverse-transcribed for 1 h at 42 °C using an
oligo(dT)12–18 primer (Invitrogen) and the SuperScript II RT
kit (Invitrogen). Quantitative real-time PCR was performed
using the SYBR Green PCR core reagents mix (Applied Bio-
systems) containing 1 SYBR Green PCR buffer, 3 mM
MgCl2, 100 M dATP, dCTP, and dGTP, 200 M deoxyuri-
dine triphosphate, 0.025 units/l AmpliTaq Gold DNA
polymerase, 0.01 units/l AmpErase uracil N-glycosylase,
and 2 pmol/l gene-specific forward and reverse primers
designed by the Eurofins MWG Operon: IL-8 forward (CT-
TGTCATTGCCAGCTGTGT) and reverse (TGACTGTGG-
AGTTTTGGCTG); TNF- forward (TGGCCAATGGCGT-
GGAGCTG) and reverse (AGACGGCGATGCGGCTGA-
TG). The reaction conditions were as follows: 2 min at 50 °C
(1 cycle), 10 min at 95 °C (1 cycle), 15 s at 95 °C, and 1 min at
60 °C (40 cycles). Gene-specific PCR products were ampli-
fied using an Applied Biosystems PRISM 7500 detection sys-
tem (PerkinElmer Life Sciences). Samples were normalized
using the 18 S ribosomal unit as a housekeeping gene. Three
replicates for each experimental point were performed, and
differences were assessed with the two-tailed Student’s t test.
Results are expressed as the relative -fold changes of the
stimulated over the control group, which was used as a
calibrator.
StatisticalAnalysis—Differences between themeans of treat-
ments were analyzed by the Student’s t test using GraphPad
Prism Version 4 (GraphPad Software, San Diego, CA). Differ-
ences betweenmultiple treatments were compared by one-way
analysis of variance followed by Tukey’s post test. Values are
expressed as the mean  S.E. A value of p  0.05 was consid-
ered to represent a statistically significant difference (*, p 
0.05; **, p 0.01; ***, p 0.001).
RESULTS
Effect of E. coli and P. gingivalis LPS Retreatment on IB-
Degradation in THP-1 Cells—Because activation of NF-B is
indispensable for proinflammatory gene activation, we
detected IB- degradation in THP-1 cells. Control and either
E. coli LPS-tolerized or P. gingivalis LPS-tolerized THP-1 cells
were treated with the same LPS for 15, 30, and 60 min, and
IB- was detected by Western blot. 1 g/ml E. coli LPS
induced rapid degradation of IB- in control human mono-
cytes, but in E. coli LPS-tolerized cells re-treated with the same
LPS (1 g/ml), IB- degradation was significantly reduced
(Fig. 1).
Degradation of IB- in THP-1 cells treated with 1 g/ml
P. gingivalis LPS occurred with similar kinetics to monocytes
treated with E. coli LPS. However, repeated treatment with
P. gingivalis LPS failed to induce significantly reduced degrada-
tion of IB-, indicating that in contrast to E. coli LPS-tolerized
cells, these monocytes were still responsive (Fig. 2).
Effect of E. coli and P. gingivalis LPS Retreatment on TNF-
and IL-8 Expression in THP-1Cells—Due to the involvement of
the NF-B pathway in the expression of both TNF- and IL-8
genes, we examined transcription of both genes in control and
tolerizedmonocytes. Both E. coli and P. gingivalis LPS induced
a significant increase in TNF- and IL-8 mRNA in THP-1
cells after the first treatment. In E. coli LPS-re-treated cells
transcription of both genes was significantly reduced; how-
ever, in P. gingivalis LPS-re-treated cells IL-8 expression
remained high, whereas TNF- expression significantly
dropped (Table 1).
In agreement with detected levels of TNF- and IL-8 mRNA
after initial challenge with 1 g/ml E. coli LPS, THP-1 cells
responded by producing high levels of IL-8 and TNF-.
Repeated challenge of THP-1 cells with the same concentration
FIGURE 1. IB- degradation in THP-1 cells after the first and repeated
challenge with 1 g/ml E. coli LPS. Control and E. coli LPS tolerized THP-1
cellswere treatedwith 1g/ml E. coli LPS for the indicated timepoints.Whole
cell lysates were immunoblotted for IB- and GAPDH as a loading control.
Blots are representative of three separate experiments.
FIGURE 2. IB- degradation in THP-1 cells after the first and repeated
challengewith1g/mlP.gingivalisLPS.Control andP. gingivalisLPS-toler-
ized THP-1 cells were treated with 1 g/ml P. gingivalis LPS for the indicated
time points. Whole cell lysates were immunoblotted for IkB- and GAPDH as
a loading control. Blots are representative of three separate experiments.
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of E. coli LPS significantly decreased production of both cyto-
kines (p  0.01) (Fig. 3, a and b). THP-1 cells treated with 1
g/ml P. gingivalis LPS responded in a similar manner as cells
treated with E. coli LPS. However, repeated challenge with
P. gingivalis LPS almost completely abolished production of
TNF- (p  0.01), whereas IL-8 concentration remained as
high as it was after the first challenge (Fig. 3, a and b).
Taken together, these results suggest the existence of differ-
ent regulatory mechanisms for TNF- and IL-8 secretion in
endotoxin-re-treated monocytes. IL-8 secretion in tolerized
cells is signaling-dependent, whereas production of TNF- is
controlled at the transcriptional level. Furthermore, TLR2-in-
duced endotoxin tolerance is only partial, with persistently high
secretion of IL-8 but reduced production of TNF-.
Evaluation of E. coli LPS and P. gingivalis LPS Cross-
tolerance—To examine if biologically active substances
secreted during 24 h of pretreatment influence the induction of
endotoxin tolerance, cross-tolerance betweenE. coli andP. gin-
givalis LPS was examined. THP-1 cells were tolerized with
E. coli LPS and then re-treated with P. gingivalis LPS and vice
versa. After 4 h of re-treatment, the production of IL-8 and
TNF- was measured in the cell supernatants. E. coli LPS
induced cross-tolerance after subsequent exposure to P. gingi-
valis LPS, and the concentrations for both IL-8 and TNF-
were significantly lower in comparison to control cells. Inter-
estingly, in the cells tolerized with P. gingivalis LPS and
re-treated with E. coli LPS, TNF- production dropped signif-
icantly, but IL-8 levels remained at similar levels to those
observed in control cells (Figs. 4, a and b).
Influence of Interferon  on Induction of Endotoxin Tolerance
in THP-1 Cells—Because P. gingivalis LPS is a TLR2 agonist
and activates only the MyD88-dependent pathway, whereas
E. coli LPS activates both MyD88-dependent and TRIF path-
way, we examined the influence of IFN- as a product of the
TRIF pathway on induction of immune tolerance. First, we
observed that the concentration of IFN- was significantly
higher in the THP-1 cells treated with E. coli LPS for 24 h than
in those treated with P. gingivalis LPS (Fig. 5). Furthermore,
concentrations of IFN- in supernatants of human gingival
fibroblasts, the cells that do not display endotoxin tolerance,
treated with either E. coli LPS or P. gingivalis LPS were unde-
tectable (data not shown).
FIGURE3.Productionof IL-8 (a) andTNF- (b) byTHP-1 cells after the first
and repeated challenge by 1 g/ml E. coli (E.c) LPS or P. gingivalis (P.g)
LPS. Values represent the mean S.E. of n 3.
FIGURE 4. IL-8 (a) and TNF- (b) production by THP-1 cells cross-tolerized
with E. coli (E.c) LPS andP. gingivalis (P.g) LPS. THP-1 cells were pretreated
with 1 g/ml E. coli LPS for 24 h and re-treated with 1 g/ml P. gingivalis LPS
for 4 h or vice versa. Control THP-1 cells were incubated inmedium alone and
re-treated with 1g/ml E. coli or P. gingivalis LPS. Supernatant was removed,
and IL-8 and TNF- levels were assessed by ELISA.
TABLE 1
Differential regulation of IL-8 and TNF-mRNA expression in E. coli and P. gingivalis LPS-tolerized cells
RT-PCR analysis of TNF- and IL-8 gene expression in control and tolerizedTHP-1 cells shows selective inhibition of TNF- only inP. gingivalisLPS-tolerized cells. THP-1
cells were pretreated with 1 g/ml concentrations of either E. coli LPS or P. gingivalis LPS and re-treated with the same LPS. Numbers show -fold increase in TNF- and
IL-8 expression by control and pretreated THP-1 cells after 4 h of LPS retreatment. 18 SmRNAwas used for the internal control. Values represent the -fold increase S.E.
of three different experiment.
Cytokine Medium/Medium Medium/E. coli LPS E. coli LPS/E. coli LPS Medium/P. gingivalis LPS P. gingivalis LPS/P. gingivalis LPS
IL-8 1 943.4 83.2 214.8 38.6*** 815.2 61.7 796.0 53.4
TNF- 1 114.7 28.3 23.3 7.9*** 107.4 18.4 27.8 4.9***
***, p 0.001.
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To examine the influence of IFN- on induction of endo-
toxin tolerance, recombinant human IFN- (0.1 ng/ml) was
used during P. gingivalis LPS 24-h pretreatment. This particu-
lar concentration of IFN- was chosen as it approximated the
concentration of IFN- detected in THP-1 cells supernatants
treatedwithE. coliLPS for 24 h.On the other hand, the addition
of an anti-IFN- antibody during the E. coli LPS 24-h pretreat-
ment was used to neutralize the IFN- effect. Subsequently, the
cells were re-treated with the same LPS and IB- degradation,
and IL-8 and TNF- production were measured.
In THP-1 cells pretreated with 1 g/ml P. gingivalis LPS in
combination with 0.1 ng/ml IFN- for 24 h and re-treated with
the same LPS for 15, 30, and 60 min, IB- degradation was
delayed in comparison to THP-1 cells pretreated only with
P. gingivalis LPS (Fig. 6). ELISA results revealed that the addi-
tion of IFN- during the 24-h P. gingivalis LPS pretreatment
caused significantly decreased production of IL-8 in P. gingiva-
lis LPS rechallenged cells. The addition of IFN--neutralizing
antibody during E. coli LPS pretreatment recovered IL-8 pro-
duction by THP-1 cells re-treated with the same LPS. Isotype-
matched control antibody did not influence IL-8 secretion after
repeated challenge with E. coli LPS (Fig. 7). Interestingly, the
addition of IFN--neutralizing antibody during the 24-h E. coli
LPS pretreatment did not alter the endotoxin tolerant state of
THP-1 cells with respect to TNF- production (Fig. 8).
Our results show that IL-8 and TNF- production in endo-
toxin-tolerant cells is controlled by a different mechanism and
at distinct levels. In addition, IFN- is responsible for induction
of endotoxin tolerance with respect to IL-8 production, and the
relative absence of IFN- due to signaling only via the MyD88-
dependent pathway may in fact explain the lack of endotoxin
tolerance to IL-8 secretion after repeated challenge with P. gin-
givalis LPS.
Evaluation of E. coli LPS and P. gingivalis LPS Induced Endo-
toxin Tolerance in Wild-type and IRF3-deficient Mouse Bone
Marrow-derivedMacrophages—Inwild-typemouse bonemar-
row-derived macrophages, similar to THP-1 cells, TNF- pro-
duction was significantly down-regulated in the cells re-treated
with eitherE. coliLPSorP. gingivalisLPS, but production of the
chemokines KC andMIP-2 decreased only in E. coli LPS-toler-
ized cells (Fig. 9a). In contrast to wild type, IRF3/ macro-
phages behaved in the same manner when treated with either
E. coli or P. gingivalis LPS. Notably, only TNF- production
was down-regulated in tolerized IRF3/ macrophages,
whereas production of KC and MIP-2 remained high in both
E. coli and P. gingivalis LPS-re-treated cells (Fig. 9b).
Interferon  Induces Endotoxin Tolerance in Non-tolerant
Human Gingival Fibroblasts—Human gingival fibroblasts,
widely known not to display the phenomenon of endotoxin
tolerance, were used to further examine the influence of IFN-
on induction of the tolerant state. HGF were pretreated with
either 10 ng/ml E. coli LPS or 10 g/ml P. gingivalis LPS in
combination with different concentrations of IFN- (0.1, 0.2,
0.5 ng/ml) followed by LPS re-treatment for 4 h. IL-8 concen-
trations detected in HGF supernatants are presented in Fig. 10.
FIGURE 5. IFN- production assessed in THP-1 cells supernatants treated
with1g/ml E. coli LPSandP. gingivalis LPS for 24h.Values represent the
mean S.E. of n 3.
FIGURE 6.Theadditionof rIFN-duringP. gingivalis (P.g) LPSpretreatmentdelays IB-degradationafter repeated challengewithP. gingivalis LPS.
THP-1 cells were pretreated for 24 hwithmediumalone (a), 1g/ml P. gingivalis LPS (b), and a combination of 1g/ml P. gingivalis LPS and 0.1 ng/ml IFN- (c).
Cells were washed and re-treatedwith 1g/ml P. gingivalis LPS for the indicated time points. Whole cell lysates were immunoblotted for IB- and GAPDH as
a loading control. Blots are representative of three separate experiments.
FIGURE 7. The addition of rIFN- during 24 h P. gingivalis (P.g) LPS pre-
treatment significantly decreases production of IL-8 by THP-1 cells after
repeated exposure to P. gingivalis LPS. Neutralizing IFN- antibody
included during E. coli (E.c) LPS pretreatment recovered IL-8 production by
THP-1 cells re-treated with E. coli LPS. Isotype control antibody did not have
influenceonestablishment of endotoxin tolerance. rIFN- alone is not able to
induce endotoxin tolerance. IL-8 in cell supernatants was assessed by ELISA.
Values represent themean S.E. of n 3 (endotoxin activity of rIFN- 0.1
ng/g).
Altered Endotoxin Tolerance and Chronic Inflammation
29496 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 34•AUGUST 26, 2011
 at Aberdeen University, on O
ctober 10, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
IFN-, included as a co-stimulus during induction of endotoxin
tolerance, significantly decreased the production of IL-8 in a
dose-dependent manner after repeated challenge with both
E. coli and P. gingivalis LPS in otherwise non-tolerant HGFs.
DISCUSSION
The immune system needs to constantly strike a balance
between activation and inhibition to avoid detrimental and
inappropriate inflammatory responses, and as a result TLR sig-
naling must be tightly regulated to maintain immunological
balance. TLR activation is a double-edged sword. It is essential
for provoking the innate response and enhancing adaptive
immunity against pathogens (30). However, the signal that is
transmitted from TLRs must be well controlled, and there is
clear evidence that if TLRs are overactivated, infectious and
inflammatory disease can result (31). It has been shown that
members of the TLR family are involved in the pathogenesis of
autoimmune, chronic inflammatory, and infectious diseases
such as periodontitis, chronic obstructive pulmonary disease,
asthma, atherosclerosis, and systemic lupus erythematosus
(32).
Endotoxin tolerance is a mechanism for regulation of the
immune response and is defined as transient unresponsiveness
to repeated doses of LPS (33). The significance of this refractory
state of the hypo-responsiveness has been revealed by studies
demonstrating that macrophages from surviving septic shock
patients display LPS tolerance (34). Functionally, endotoxin-
tolerant monocytes/macrophages exhibit an increased phago-
cytic ability coupled with a conserved capacity to kill internal-
ized pathogens, albeit with an impaired antigen presentation
capacity (35). Considering the in vivo relevance of the above
phenotype, poor inflammatory capacity coupled with up-regu-
lation of anti-inflammatory cytokines could contribute to pro-
FIGURE 8. IFN- does not have effect on decreased production of TNF-
after repeated challengewith E. coli LPS. THP-1 cells were pretreated with
medium alone, 1 g/ml E. coli (E.c) LPS, 1 g/ml E. coli LPS  1 g/ml anti-
IFN antibody, and 1 g/ml E. coli LPS  1 g/ml isotype control antibody
and re-treatedwith 1g/ml E. coli LPS. TNF-wasmeasured in the cell super-
natants by ELISA. Values represent the mean S.E. of n 3.
FIGURE 9.Wild-typemousebonemarrow-derivedmacrophages reflect the cytokinepatternproducedbyTHP-1 cells,whereas IRF3/macrophages
down-regulateonlyTNF-productionafter repeatedchallengewitheitherE. coliLPS (E.c) orP. gingivalis (P.g) LPS.Wild-type (a) and IRF3 knock-out (b)
bone marrow-derived macrophages (5 105 cells/ml) were pretreated with medium alone, 100 ng/ml E. coli LPS, or 100 ng/ml P. gingivalis LPS for 24 h and
re-treated with the same agonists for 4 h. Mouse MIP-2, KC, and TNF-weremeasured in the cells supernatants by ELISA. Values represent themean S.E. of
n 3.
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tection against tissue damage, and increased phagocytosis
would allow efficient bacterial clearance.
LPS tolerance has traditionally been viewed as a hyporespon-
sive state of immune cells resulting from receptor desensitiza-
tion, and the majority of studies have concentrated on
decreased production of TNF- after repeated exposure to
canonical E. coli LPS and its interaction with TLR4 (36). How-
ever, comparison of the LPS molecules of different organisms
revealed that there are structural differences in the chemical
composition of naturally occurring lipid A. The number of
phosphate groups attached to the glucosamine backbone and
the number and length of acyl chains determine whether the
LPS will be a TLR4 or TLR2 agonist (37). Based on current
evidence, it seems that rather being the exception to the rule,
TLR2 signaling LPS may be commonly represented among
Gram-negative species (20).
We show here that non-canonical, TLR2-stimulating LPS
from P. gingivalis, a key factor in the development of neutro-
phil-dominated chronic inflammation associated with perio-
dontitis, exhibits impaired endotoxin tolerance compared with
E. coli LPS in both the cell line (THP-1) and primary cells (bone
marrow-derived macrophages). TLR2 induced immune toler-
ance by repeated challenge with peptidoglycan, Pam3CSK4,
and P. gingivalis LPS has been described before but only with
respect to TNF- production (38, 39). Our current data indi-
cate that the cytokine network produced by THP-1 cells and
mouse bone-derived macrophages repeatedly challenged with
TLR2-activating LPS (P. gingivalis LPS) differs from those
treatedwithTLR4-activating LPS (E. coli LPS). TNF- and IL-8
production in THP-1 cells and TNF-, KC, and MIP-2 in
mouse macrophages were significantly reduced after repeated
challenge by E. coli LPS, whereas persistent high production of
IL-8 as well as KC and MIP-2 accompanied with diminished
secretion ofTNF-was observed inP. gingivalisLPS-re-treated
cells. In addition, we demonstrated that impaired endotoxin
tolerance induced by the LPS-TLR2 complex occurs as a result
of the inability of TLR2 agonists to produce significant amounts
of IFN-, which is responsible for inhibition of NF-B
activation.
We also showed that in endotoxin-tolerant cells there are
different regulatory mechanisms for the expression of genes
that belong to the same functional category (proinflammatory
cytokines). Both IL-8 and TNF- are secreted principally as a
response to MyD88-dependent pathway activation and NF-B
nuclear translocation. Nevertheless, IL-8 gene expression in
endotoxin-tolerant cells was signaling-specific, whereas tran-
scription of TNF- gene did not correlate with activation of the
NF-B pathway. The inability of P. gingivalis LPS as a TLR2
agonist to reduce degradation of IB- after repeated challenge
resulted in a persistent high production of IL-8 in contrast to
TNF- production that was significantly down-regulated. Dif-
ferences in IBproteins degradation have also been reported by
Martin et al. (40) who observed maintained degradation of
IB- after repeated challenge by P. gingivalis LPS but not
E. coli LPS. High concentrations of IL-8 have been found in
gingival crevicular fluid from periodontitis patients, suggesting
an important role for this potent chemokine in the disease
pathogenesis (41). Furthermore, Muthukuru et al. (42)
reported thatmonocytes fromperiodontitis patientsweremore
resistant to down-regulation of IL-8 production after repeated
challengewithP. gingivalisLPS comparedwith other cytokines.
In a broader view of chemokines, Foster and Medzhitov (43)
showed that in mouse bone marrow macrophages, genes for
chemokine ligand 9 (Cxcl9) and chemokine ligand 8 (Ccl8)
belonged to the “non-tolerizeable” genes group whose promot-
ers are open after repeated challengewith LPS. Transcription of
such open promoter requires an LPS signal that induces NF-B
activation and its binding to the DNA promoter regions.
In contrast to IL-8 expression, which is signaling-dependent,
it has been shown that production of TNF- in endotoxin-tol-
erant cells is controlled at the level of transcription. The silenc-
ing of TNF- production in endotoxin-tolerant THP-1 cells is a
result of dimethylation on histone H3 at the TNF- promoter.
This process correlates with diminished binding of the active
NF-B to the promoter and decreased production of TNF-
(28). This could explain differential production of IL-8 and
TNF- bymonocytes/macrophages repeatedly challengedwith
P. gingivalis LPS.We can speculate that despite persistent acti-
vation of the NF-B pathway in P. gingivalis LPS-re-treated
monocytes, TNF- production was reduced due to histone
remodeling at its promoter region, whereas IL-8 remained high
FIGURE 10. Interferon  included as a co-stimulant during LPS pretreat-
ment induces endotoxin tolerance in human gingival fibrobalsts after
repeatedchallengewithbothE. coliLPS (a) andP. gingivalisLPS (b) (con-
centrations of IFN- are in ng/ml).HGFs (8 104 cells/ml) were pretreated
with 10 ng/ml E. coli LPS or 10 g/ml P. gingivalis LPS with or without the
addition of rhIFN- for 24 h and re-treatedwith the same LPS for 4 h. IL-8 was
measured in the cells supernatants. Values represent themeanS.E. ofn3.
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because of uninterrupted binding of NF-B to IL-8 non-modi-
fied promoter.
Interleukin 8 aswell as itsmouse counterparts KC andMIP-2
are principal mediators of the inflammatory response that
attract leukocytes to the site of infection leading to neutrophil
infiltration,which if not controlledmay culminate in host tissue
damage. Therefore, down-regulation of chemokine production
is vital in the prevention of chronic inflammation (45). Results
obtained from heterotolerance experiments where THP-1 cells
pretreated with E. coli LPS and re-treated with P. gingivalis LPS
displayed a decrease in IL-8 production, whereas P. gingivalis
LPS pretreatment did not have an effect on IL-8 production
afterE. coliLPS rechallenge, prompted us to examine the role of
IFN- on chemokine secretion in endotoxin tolerant cells.
First, we observed significantly higher production of IFN-
after 24 h of treatment ofTHP-1 cellswithE. coliLPS compared
with the same treatment with P. gingivalis LPS. Similar findings
were reported by Dobrovolskaia et al. (46) and Toshchakov et
al. (47), who found poorly induced IFN- gene in murine
macrophages in response to TLR2 activation. Interestingly,
IFN- concentrations in human gingival fibroblasts superna-
tants treated for 24 hwith eitherE. coli or P. gingivalis LPSwere
undetectable, and these cells were even primed to subsequent
LPS challenge with respect to IL-8 production. Second, we
included recombinant IFN- during P. gingivalis LPS pretreat-
ment and neutralizing IFN- antibody during E. coli LPS pre-
treatment of THP-1 cells. We found that pretreatment with
P. gingivalis LPS in combination with rIFN- delayed degrada-
tion of IB- and significantly decreased production of IL-8
after repeated challenge with P. gingivalis LPS. Interestingly,
the addition of IFN- neutralizing antibody during the E. coli
LPS pretreatment only partially alleviated tolerance to E. coli
LPSwith respect to IL-8 production, indicating the existence of
other regulatory mechanisms. Using a mouse model, Shah-
angian et al. (48) demonstrated a less effective response with
regard to KC and MIP-2 production in wild-type influenza-
infected mice secondary challenged with Streptococcus pneu-
moniae in comparison to mice deficient for type IFN-/
receptor. IRF3 transcription factor is essential for lipopolysac-
charide-induced interferon  gene expression (49). We have
shown in IRF3-deficient macrophages that there is no differ-
ence inKC andMIP-2 production after repeated challengewith
either E. coli or P. gingivalis LPS. Sustained high production of
KC and MIP-2 by tolerized IRF3 knock-out macrophages con-
firms an important role of interferon  in chemokine down-
regulation during the state of endotoxin tolerance. In addition,
co-stimulation of HGFs with IFN- and LPS induced signifi-
cantly lower production of IL-8 after repeated challenge with
LPS in these cells, which normally do not display endotoxin
tolerance. IFN- has been shown to prime human gingival
fibroblasts to subsequent LPS response but to decrease IL-8
production if incubated at the same time with LPS (50).
An essential function of IFN- is its antiviral activity, which
affects almost all cell types infected with a broad spectrum of
viruses. Additionally, and perhaps more important for its
involvement in endotoxin tolerance, IFN- has anti-prolifera-
tive and immunomodulatory functions (51). It has been used
successfully as one of the therapy options for patients withmul-
tiple sclerosis (52). With respect to endotoxin tolerance, it has
been shown that in contrast to theMyD88-dependent pathway,
which is down-regulated during TLR4-induced endotoxin tol-
erance, the TRIF pathway and production of IFN- are up-reg-
ulated (53). Furthermore, Biswas andTergaonkar (8) reported a
direct effect on IFN- onTNF- production byTLR4-tolerized
murine macrophages but not in TLR2-tolerized cells. In our
study, pretreatment of human monocytic cells line with IFN-
on its own did not make them tolerant to subsequent E. coli or
P. gingivalis LPS challenge, whereas in combinationwith P. gin-
givalis LPS it successfully inhibited production of IL-8 after
repeated exposure to the same LPS.
TLR2 has been found to be involved inmany chronic inflam-
matory diseases. Elevated expression of proinflammatory cyto-
kines in periodontitis patients has been assigned to TLR2-in-
duced and -amplified response (54). Studies on chronic
inflammation in the human gastric mucosa caused byH. pylori
infection showed involvement of TLR2 as well (55). The
absence of TLR2 protein expression by intestinal epithelial cells
has been shown to be important in preventing chronic proin-
flammatory cytokine secretion in response to commensal bac-
teria in the gut (56), whereas up-regulation of TLR4 expression
in colon protects mice from colitis (44).
Our study indicates that impaired and partial endotoxin tol-
erance induced in monocytes/macrophages by non-canonical,
TLR2-activating LPS, characterized by persistent high secre-
tion of IL-8 due to the lack of immunomodulatory effect of
IFN-, could be responsible for detrimental consequences of
chronic TLR2 activation.
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